

**IN THE MATTER OF**

**\* BEFORE THE MARYLAND**

**AMINAT ADEKOYA**

**\* STATE BOARD OF**

**Respondent**

**\* PHARMACY**

**License Number: 21722**

**\* Case Number: 25-268**

**\***

**\* \* \* \* \***

**ORDER FOR SUMMARY SUSPENSION OF  
PHARMACIST LICENSE**

The Maryland Board of Pharmacy (the “Board”) hereby summarily suspends the license of **AMINAT ADEKOYA** (the “Respondent”), License Number **21722**, to practice pharmacy in the State of Maryland. The Board takes such action pursuant to the Board’s authority under Md. Code Ann., State Gov’t § 10-226(c)(2) (2021 Repl. Vol. & 2024 Supp.) and Code of Maryland Regulations (“COMAR”) 10.34.01.12F, concluding that the public health, safety, or welfare imperatively requires emergency action. This Order is based on the following investigative findings, which the Board has reason to believe are true:

**INVESTIGATIVE FINDINGS<sup>1</sup>**

1. At all times relevant hereto, the Respondent was licensed to practice pharmacy in the State of Maryland. The Respondent was originally licensed to practice

---

<sup>1</sup> The statements regarding the Respondent’s conduct are intended to provide the Respondent with notice of the allegations. They are not intended as, and do not necessarily represent a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in connection with this matter.

pharmacy in Maryland on July 22, 2013, under license number 21722. The Respondent's license is scheduled to expire on March 31, 2027.

2. At all times relevant hereto, the Respondent was employed as a pharmacist at a pharmacy (the "Pharmacy")<sup>2</sup> located in Wicomico County, Maryland.

3. On or about January 17, 2025, the Pharmacy notified the Board that the Pharmacy terminated the Respondent "due to violations of company policy." Following receipt of the notification, the Board investigated.

4. The Board obtained a copy of an investigatory report from the Pharmacy. According to the report, on or about November 18, 2024, the Pharmacy identified four (4) prescriptions for phentermine<sup>34</sup> from the same provider as suspicious for possible drug diversion. The four prescriptions were inconsistent with the provider's history at the Pharmacy. The provider is a physician's assistant at an urgent care facility who had 659 prescriptions filled at the Pharmacy, but the only prescriptions from the provider for controlled dangerous substances ("CDS") were the four phentermine prescriptions. The Respondent filled the four prescriptions, recording that the prescriptions were transmitted from the provider via telephone. The four prescriptions were purchased using cash. For the most recent of the four prescriptions, closed circuit television revealed that the Respondent completed the purchase. The Respondent scanned her driver's license to complete this purchase.

---

<sup>2</sup> In order to maintain confidentiality, names of individuals and facilities involved in this matter will not be used in this document but will be provided to the Respondent on request.

<sup>3</sup> Phentermine, a Schedule IV CDS, is used to speed weight loss by decreasing appetite.

<sup>4</sup> The Board does not allege that any of the medications identified in this document were obtained for legitimate medical purposes.

5. The four prescriptions were purchased using two patient profiles (not in Respondent's name) with one of the patient profile's addresses bearing similarity to the Respondent's address on file with the Pharmacy. The Pharmacy further identified additional transactions involving these patient profiles.

6. On or about January 9, 2025, the Pharmacy interviewed the Respondent. The Respondent initially denied creating patient profiles for patients that do not exist. However, upon being shown documentation that the Respondent's driver's license was scanned to purchase drugs using the patient profiles, the Respondent admitted the following:

[The Respondent] admitted that she knew the Physician's Assistant at a local Urgent Care who had been forging the fake prescriptions, via call in. [The Respondent] stated, that the activity had been occurring for over a year, and previously at her store that had closed. She explained that the Physician's Assistant would call in prescriptions, which [the Respondent] would then fill for herself. She also revealed that the fake profile had been created two years ago, while at her former store. [The Respondent] went further to say, she had known her Urgent Care contact since pharmacy school, and they [were] friends. I began listing all the drugs [the Respondent] had purchased with the fake prescriptions over the last year, totaling nine times. [The Respondent] confirmed that she had been picking up the medications, some of which were controlled drugs.

7. The Board obtained a written statement, authored by the Respondent on or about January 9, 2025, acknowledging that she created a fictitious patient profile and used

it to fill and purchase prescriptions for phentermine, cyclobenzaprine,<sup>5</sup> tizanidine,<sup>6</sup> and gabapentin.<sup>7</sup>

8. The Board obtained the Pharmacy's records for the patient profiles and the related prescription transactions. Each prescription was recorded as having been transmitted via telephone by the same provider. The fictitious patient profiles were used to purchase with cash, from approximately February 15, 2023, through November 18, 2024: four (4) prescriptions for 60 tablets of phentermine 37.5 mg; two (2) prescriptions for 270 tablets of tizanidine hydrochloride 4 mg; one (1) prescription for 90 capsules of gabapentin 300 mg; one (1) prescription for 90 tablets of cyclobenzaprine 10 mg; one (1) prescription for 90 tablets of ibuprofen 800 mg; and (vi) one (1) prescription not disclosed in this document for privacy reasons.

9. The Board obtained court records, including an Application for Statement of Charges and Statement of Charges, in the District Court of Maryland for Wicomico County, Maryland in Case No. D-023-CR-25-000020. According to the court records, the Respondent is charged in that case with three (3) counts of obtaining a prescription drug by fraud.

---

<sup>5</sup> Cyclobenzaprine is a prescription-only skeletal muscle relaxant used to relax muscles and relieve pain and discomfort caused by strains, sprains, and other muscle injuries.

<sup>6</sup> Tizanidine is a prescription-only skeletal muscle relaxant used to relieve the spasms and increased muscle tone caused by multiple sclerosis, stroke, or brain or spinal injury.

<sup>7</sup> Gabapentin is a prescription-only anticonvulsant used to help control seizures in people who have epilepsy.

10. Based on the above information, the Board has reason to believe that the Respondent diverted multiple prescriptions drugs and/or CDS while employed as a pharmacist at the Pharmacy.

**CONCLUSION OF LAW**

Based on the foregoing Investigative Findings, the Board concludes as a matter of law that the public health, safety, or welfare imperatively requires emergency action in this case, pursuant to State Gov't. § 10-226(c)(2) and COMAR 10.34.01.12F.

**ORDER**

Based on the foregoing Investigative Findings and Conclusions of Law, it is this 8<sup>th</sup> day of April 2025, by a majority of the quorum of the Board, hereby:

**ORDERED** that pursuant to the authority vested in the Board by Md. Code Ann., State Gov't § 10-226(c)(2), the Respondent's license to practice pharmacy, License Number **21722**, in the State of Maryland be and is hereby **SUMMARILY SUSPENDED**; and it is further

**ORDERED** that the Respondent shall immediately return all registrations and licenses to the Board; and it is further


**ORDERED** that the Respondent has the opportunity to appear before the Board for a post-deprivation show cause hearing. A request for a post-deprivation show cause hearing must be in writing and be made **WITHIN THIRTY (30) DAYS** of receipt of this order; and it is further

**ORDERED** that if the Respondent does not submit a timely written request to the Board for a post-deprivation show cause hearing, or if the Respondent requests a post-

deprivation show cause hearing but fails to appear when scheduled, the investigative findings contained in this Order shall stand and the Respondent's license to practice pharmacy will remain **SUSPENDED** absent any further action by the Board; and be it further

**ORDERED** that this is a **PUBLIC DOCUMENT** pursuant to the Maryland Public Information Act. Md. Code Ann., Gen. Prov. §§ 4-101 – 4-601 (2019 Repl. Vol. & 2024 Supp.).

4-8-25  
Date

  
\_\_\_\_\_  
Deena Speights-Napata  
Executive Director  
Maryland Board of Pharmacy

4-8-52

W. H. R. R. R. R. R.